Trial Profile
Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Necrosis; Soft tissue infections
- Focus Therapeutic Use
- Acronyms INSTINCT
- 17 Jun 2021 Results (n=100) of post-hoc analysis assessing the effect of IVIG on various inflammatory cytokines up to day 3 after randomization in patients with soft-tissue infection, published in the Acta Anaesthesiologica Scandinavica.
- 29 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.